24th Annual Meeting of the Japanese Society of Clinical Neuropsychopharmacology
jointly with 44th Annual Meeting of Japanese Society of Newropsychopharmacology

November 20-22, 2014
Nagoya Congress Center

FIRST AUTHOR INDEX
First Name	Last Name	No.	Title
Harvey	Philip	SL-1	Newest Developments in the Assessment and Treatment of Cognition and Disability in Schizophrenia
Manji	Husseini K.	SL-2	Targeting Synaptic & Neural Plasticity to Develop Improved Rx’s for Severe Mood Disorders
Kim	Hyoung-Chun	S10-1	Role of IL-6 in the neurotoxicity and cognitive dysfunction induced by convulsant
Saito	Kuniaki	S10-2	The role of L-tryptophan metabolism via indoleamine 2,3-dioxygenase on cytokine-induced depressive symptoms
Yamada	Kiyofumi	S10-3	Molecular mechanism of neurodevelopmental disorders associated with perinatal aberrant neuroimmune responses
Niwa	Minae	S10-4	Dopaminergic disturbance and behavioral deficits in mental illness: Roles of stress and glucocorticoids
Kato	Takahiro	S10-5	Psychosocial stress and microglia-translational research focusing on human microglia
Kimura	Hiroshi	PJ-1	A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis
Takeuchi	Hiroyoshi	PJ-2	Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients with Schizophrenia: An Open-label, Randomized, Controlled, Pilot Study
Suzuki	Yutaro	EN-3	Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia
Harvey	Philip	LS07	The Role of the dopamine D3 receptor in Cognition and Disability in Schizophrenia
Andersen	Peter Høngaard	AS01	Development of the curative medicine to the psychiatric disorders (especially depression, mood disorders) by industrial, administrative and academic sectors cooperation
Kane	John M.	SpS4-1	Consider the therapeutic goals: Recovery
Tsuboi	Takashi	O1-E2	Challenging the Need for High and Sustained Dopamine D2 Receptor Blockade in the Maintenance Treatment of Schizophrenia: A Single-Blind, Randomized, Controlled Study
Ishioka	Masamichi	O1-F6	Hyperprolactinemia during antipsychotic treatment increases the risk for venous thromboembolism
Tsuneyama	Nobuto	O1-F7	Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia
Shinfuku	Masaki	O1-F9	Effectiveness of Long-term Benzodiazepine Use in Anxiety Disorders: A Systematic Review
Moriya	Shunpei	O3-F2	Effect of quetiapine on Per1, Per2, and Bmal1 clock gene expression in the mouse amygdala and hippocampus
Odagaki	Yuji	O3-F9	Selective interaction between adenosine receptors and Gi-3 in postmortem human brain membranes
Mizoguchi	Kazushige	O3-F13	Specific binding and characteristics of 18β-glycyrrhetinic acid in the rat brain
Kato	Masaki	P1-1	Genome-wide interaction and pathway analysis on SSRI response in Japanese patient with major depression
Matsumoto	Yoshihiko	P1-4	Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder
Kishi	Taro	P1-7	The Position of Blonanserin as a Treatment for Schizophrenia
Kishi	Taro	P1-8	Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Harvey	Philip	P1-13	IMPACT OF IMPROVED INSIGHT IN SCHIZOPHRENIA: A DOUBLE-BLIND LURASIDONE AND QUETIAPINE XR STUDY
Oya	Kazuto	P1-19	Efficacy and Tolerability of Minocycline Augmentation Therapy in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Oya	Kazuto	P1-20	Efficacy and Tolerability of Histamine-2 Receptor Antagonist Adjunction of AntipsychoticTreatment in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Uchida	Hiroyuki	P1-22	Dose and Dosing Frequency of Long-Acting Injectable Antipsychotics: A Systematic Review of PET and SPECT Data and Clinical Implications
Siu	Cynthia	P1-26	Insight into illness and uncooperativeness in chronic schizophrenia
Suzuki	Yutaro	P1-32	Effects of olanzapine on the PR and QT intervals in patients with schizophrenia
Saito	Mami	P1-39	High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia
Tarumi	Ryosuke	P1-43	The evolution of augmentation therapy in the treatment of depression: a chart review
Ueno	Fumihiko	P1-45	Whether to increase or maintain dosage of mirtazapine in early non-improvers with depression
Yoshida	Kazunari	P1-50	Population pharmacokinetic analysis of lithium: a preliminary study
Matsunaga	Shinji	P1-59	Memantine Monotherapy for Alzheimer’s disease: A Systematic Review and Meta-analysis
Sasaki	Tsuyoshi	P1-63	Tipepidine in children with attention deficit/ hyperactivity disorder: a 4-week, open-label, preliminary study
Ogasa	Masaaki	P1-95	VALIDITY CHARACTERISTICS OF COGNITIVE ASSESSMENT INTERVIEW (CAI) IN STABLE OUTPATIENTS WITH SCHIZOPHRENIA
Mizoguchi	Kazushige	P2-19	Specific binding and characteristics of geissoschizine methyl ether, an alkaloid of Uncaria Hook, in the rat brain
Oshibuchi	Hidehiro	P2-39	CHRONIC HYPOACTIVITY OF RAPHE SEROTONERGIC NEURONS INHIBITS COCAINE SENSITIZATION; A STUDY USING DESIGNER RECEPTORS EXCLUSIVELY ACTIVATED DESIGNER DRUGS
Shimizu	Kunio	P2-41	Environmental Enrichment enhances hippocampal autophagy signaling in a rat animal model of posttraumatic stress disorder using a shuttle box
Nagasawa	Sarah	P2-42	The effectiveness of methylphenidate and atomoxetine in the dopamine transporter knockout (DAT-KO) mice by postnatal development
Moriguchi	Shigeki	P2-44	Function of decreased Na+/Ca2+ exchanger type 2 in AD model mice
Yamada	Makiko	P2-53	Effects of escitalopram on the amygdala dopamine release in the stress-sensitive rats
Mizuno	Yuya	P2-66	Biological and Clinical Correlates of Resilience in Patients with Schizophrenia: A Cross-sectional Study